Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADYXOTCMKTS:AKSYOTCMKTS:CHPMUOTCMKTS:WWIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADYXAdynxx$0.00$0.00▼$0.00N/A2.67833 shsN/AAKSYAksys$0.00$0.00▼$0.00N/AN/AN/AN/ACHPMUCHP Merger$10.15$10.15$10.15▼$11.02N/AN/A700 shsN/AWWINAllyMe Group$0.00$7.25▼$70.00N/AN/A133 shs100 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADYXAdynxx0.00%0.00%0.00%0.00%0.00%AKSYAksys0.00%0.00%0.00%0.00%0.00%CHPMUCHP Merger0.00%0.00%0.00%0.00%0.00%WWINAllyMe Group0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADYXAdynxxN/AN/AN/AN/AN/AN/AN/AN/AAKSYAksysN/AN/AN/AN/AN/AN/AN/AN/ACHPMUCHP MergerN/AN/AN/AN/AN/AN/AN/AN/AWWINAllyMe GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADYXAdynxx 0.00N/AN/AN/AAKSYAksys 0.00N/AN/AN/ACHPMUCHP Merger 0.00N/AN/AN/AWWINAllyMe Group 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADYXAdynxxN/AN/AN/AN/AN/AN/AAKSYAksysN/AN/AN/AN/AN/AN/ACHPMUCHP MergerN/AN/AN/AN/AN/AN/AWWINAllyMe GroupN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADYXAdynxxN/AN/A0.00N/AN/AN/AN/AN/AN/AAKSYAksysN/AN/A0.00N/AN/AN/AN/AN/AN/ACHPMUCHP MergerN/AN/A0.00∞N/AN/AN/AN/AN/AWWINAllyMe GroupN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADYXAdynxxN/AN/AN/AN/AN/AAKSYAksysN/AN/AN/AN/AN/ACHPMUCHP MergerN/AN/AN/AN/AN/AWWINAllyMe GroupN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADYXAdynxxN/AAKSYAksysN/ACHPMUCHP MergerN/AWWINAllyMe GroupN/AInsider OwnershipCompanyInsider OwnershipADYXAdynxx17.40%AKSYAksys3.80%CHPMUCHP MergerN/AWWINAllyMe GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADYXAdynxx6830,000N/ANot OptionableAKSYAksys87N/AN/ANot OptionableCHPMUCHP Merger3N/AN/ANot OptionableWWINAllyMe GroupN/AN/AN/ANot OptionableCHPMU, ADYX, AKSY, and WWIN HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comCHPMU, ADYX, AKSY, and WWIN Company DescriptionsAdynxx OTCMKTS:ADYXAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.Aksys OTCMKTS:AKSYAksys Ltd. provides hemodialysis products and services for patients suffering from end-stage renal disease, known as chronic kidney failure. The company offers an automated personal hemodialysis system, known as the Aksys PHD, a Personal Hemodialysis System (PHD System), which is designed to enable patients to perform frequent hemodialysis at alternate sites, such as their own homes. The PHD System is designed to monitor, during the treatment, various vital statistics, including the patient's blood flow rate, the amount of water removed from the patient, the length of the treatment session, and other parameters. It also evaluates the performance of the artificial kidney in removing toxins from the patient's blood prior to each treatment, as well as automatically evaluates the water treatment filters and indicates whether a replacement is required and verifies that safety systems, sensors, and alarms are operating correctly. Aksys Ltd. also provides various services, including the delivery and installation of the PHD System; technical services, including maintenance and repair of the PHD System; delivery of consumables used in dialysis, such as the water purification components and dialysate concentrate; and artificial kidney, and arterial and venous blood tubing. The company markets its products and services, primarily to healthcare providers, such as hospitals, dialysis clinics, managed care organizations, and nephrology physician groups in the United States, the United Kingdom, and Japan. Aksys Ltd. was founded in 1991 and is headquartered in Lincolnshire, Illinois.CHP Merger OTCMKTS:CHPMU$10.15 0.00 (0.00%) As of 04/22/2022CHP Merger Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses with a focus on the healthcare sector. The company was incorporated in 2019 and is based in Summit, New Jersey.AllyMe Group OTCMKTS:WWINAllyme Group, Inc. engages in providing consulting services in China principally focused on the development of new-high-tech products marketing and retail sales. It seeks to provide management advisory services to business organizations worldwide. The company intends to assist smaller developing companies in the development of business models and strategies. It offers business, marketing, financial consultancy and business modelling support to its client organizations. The company was founded on August 13, 2014 and is headquartered in Los Angeles, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
